Dr. Mikhail Kosiborod with Saint Luke’s Mid-America Heart Institute is leading a clinical trial investing the use of a diabetic drug called dapagliflozin. Apparently, a new study commenced to look the drug as a means of protecting vital organs from damage caused by...
Farxiga
Category
TrialWatch: Based on DEPICT 1 &2 AstraZeneca’s Forxiga Recommended for EMA Approval
Pharmaceutical Business Review reports that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s Forxiga (dapagliflozin) to treat adults with type 1 diabetes. TrialSite News has covered this drug in...
AstraZeneca Reports Positive Results for Phase III Trial
Zenopa reports commercial sponsor AstraZeneca experienced good news from their Phase III DECLARE-TIMI 58 trial for Farxiga (dapagliflozin), which involves 17,000 adults in 33 countries with type-2 diabetes and cardiovascular disease, or multiple cardiovascular risk...